As filed with the Securities and Exchange Commission on May 5, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Ovid Therapeutics Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
46-5270895 |
(State or other jurisdiction of
incorporation or organization) |
|
(IRS employer
identification number) |
|
|
441 Ninth Avenue, 14th Floor
New York, New York |
|
10001 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
2017 Equity Incentive Plan
(Full title of the plan)
Jeremy M. Levin, DPhil, MB BChir
Chief Executive Officer
Ovid Therapeutics Inc.
441 Ninth Avenue, 14th Floor New York, New York 10001
(646) 661-7661
(Name, address, including zip code and telephone number, including area code, of agent for service)
Copies to:
|
|
|
Thomas M. Perone
General Counsel and Secretary
Ovid Therapeutics Inc.
441 Ninth Avenue, 14th Floor New York, New York 10001
(646) 661-7661 |
|
Laura A. Berezin
Jaime L. Chase Cooley
LLP 3175 Hanover Street
Palo Alto, California 94304
(650) 843-5000 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting
company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large Accelerated Filer |
|
☐ |
|
Accelerated Filer |
|
☒ |
|
|
|
|
Non-accelerated Filer |
|
☐ |
|
Smaller Reporting Company |
|
☒ |
|
|
|
|
Emerging growth company |
|
☐ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐